Drug intelligence / Profile preview

Qingfei Zhisou paste

Development stage: Preclinical
Lead developer: Kaken Pharmaceutical
Administration: Topical

Overview

Qingfei Zhisou paste is a Traditional Chinese Medicine (TCM) formulation in paste form, currently under clinical investigation for the treatment of cough variant asthma in children. It is likely applied topically. Its therapeutic effects are believed to be mediated through anti-inflammatory actions and modulation of immune responses, similar to other related TCM formulas. These mechanisms may involve the regulation of various signaling pathways and inflammatory mediators.

Other names: 清肺止嗽贴

Targets

IL1B (Interleukin-1 beta)STAT3 (Signal Transducer and Activator of Transcription 3)ICAM1 (Intercellular Adhesion Molecule 1)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Qingfei Zhisou paste.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingfei Zhisou paste.

Explore the full profile